JP2013536442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536442A5 JP2013536442A5 JP2013526167A JP2013526167A JP2013536442A5 JP 2013536442 A5 JP2013536442 A5 JP 2013536442A5 JP 2013526167 A JP2013526167 A JP 2013526167A JP 2013526167 A JP2013526167 A JP 2013526167A JP 2013536442 A5 JP2013536442 A5 JP 2013536442A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amount
- present
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 description 23
- 239000012472 biological sample Substances 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37738710P | 2010-08-26 | 2010-08-26 | |
| US61/377,387 | 2010-08-26 | ||
| PCT/US2011/049274 WO2012027631A2 (en) | 2010-08-26 | 2011-08-26 | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536442A JP2013536442A (ja) | 2013-09-19 |
| JP2013536442A5 true JP2013536442A5 (enExample) | 2013-11-28 |
| JP6097688B2 JP6097688B2 (ja) | 2017-03-15 |
Family
ID=45724080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526167A Active JP6097688B2 (ja) | 2010-08-26 | 2011-08-26 | 抗ｈｅ４抗体を検出するための方法、ならびにｈｅ４発現細胞と関連する状態の診断および／または予後判定のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20130224772A1 (enExample) |
| EP (1) | EP2609429B1 (enExample) |
| JP (1) | JP6097688B2 (enExample) |
| CN (1) | CN103180732B (enExample) |
| AU (1) | AU2011293217A1 (enExample) |
| BR (1) | BR112013004458A2 (enExample) |
| CA (1) | CA2809368C (enExample) |
| MX (1) | MX2013002268A (enExample) |
| RU (1) | RU2600891C2 (enExample) |
| WO (1) | WO2012027631A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| CA2827618C (en) * | 2011-02-17 | 2019-08-06 | Fujirebio Diagnostics, Inc. | Compositions and methods of use for the determination of he4a |
| CN103424551B (zh) * | 2013-08-06 | 2015-08-26 | 江苏福隆生物技术有限公司 | 人附睾上皮分泌蛋白4定量测定试剂盒及其检测方法 |
| US10267802B2 (en) * | 2015-09-23 | 2019-04-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of prognosis and diagnosis of ovarian cancer |
| KR102599695B1 (ko) * | 2015-12-17 | 2023-11-07 | 에프. 호프만-라 로슈 아게 | 마커 사람 부고환 단백질 4 (he4) 기반의 폐 선암 재발의 발견 방법 및 관련 용도 |
| CN109280084B (zh) * | 2018-03-09 | 2022-04-29 | 河南大学 | 一种胶体硒标记的抗he4抗体、试剂盒及其制备方法 |
| CN109480771B (zh) * | 2018-10-17 | 2021-09-07 | 江西惠肽生物科技有限公司 | 一种卵巢肿块良恶的确定方法及确定装置 |
| CN110895279B (zh) * | 2019-11-27 | 2023-02-28 | 普健生物（武汉）科技有限公司 | 一种检测人附睾分泌蛋白4的化学发光试剂盒 |
| WO2022204017A1 (en) * | 2021-03-22 | 2022-09-29 | Curative Inc. | Immunization assessments using saliva or nasal specimen |
| CN113045663B (zh) * | 2021-04-18 | 2022-04-01 | 深圳市国创纳米抗体技术有限公司 | 一种抗he4的纳米抗体1a8及其应用 |
| CN117487018B (zh) * | 2023-09-27 | 2024-05-17 | 武汉爱博泰克生物科技有限公司 | 抗人附睾分泌蛋白4的兔单克隆抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5017342A (en) * | 1988-06-01 | 1991-05-21 | Ortho Diagnostic Systems Inc. | Device for immunoassay determinations |
| AU2002241720A1 (en) * | 2000-11-08 | 2002-06-18 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
| US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1924710B1 (en) * | 2005-09-15 | 2011-03-30 | Val-Chum, S.E.C. | Methods of diagnosing ovarian cancer |
| EP2982761B1 (en) * | 2006-01-04 | 2017-10-04 | Fujirebio America, Inc. | Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers |
| AU2007297310B2 (en) * | 2006-09-13 | 2013-11-07 | Oncimmune Limited | Improved immunoassay methods |
| KR20100015438A (ko) * | 2007-03-09 | 2010-02-12 | 트리패스 이미징, 인코포레이티드 | Ｈｅ4 모노클로날 항체 및 이의 사용 방법 |
| EP2126577B1 (en) * | 2007-03-29 | 2013-03-13 | Fujirebio Diagnostics, Inc. | Use of he4 for assessment of breast cancers |
| WO2010061393A1 (en) * | 2008-11-30 | 2010-06-03 | Compugen Ltd. | He4 variant nucleotide and amino acid sequences, and methods of use thereof |
| CN101525614A (zh) * | 2009-04-13 | 2009-09-09 | 大连美亿德生物科技有限公司 | 人卵巢癌肿瘤标志物he4酶联免疫诊断试剂盒 |
-
2011
- 2011-08-26 CA CA2809368A patent/CA2809368C/en active Active
- 2011-08-26 CN CN201180051336.5A patent/CN103180732B/zh active Active
- 2011-08-26 US US13/818,466 patent/US20130224772A1/en not_active Abandoned
- 2011-08-26 AU AU2011293217A patent/AU2011293217A1/en not_active Abandoned
- 2011-08-26 WO PCT/US2011/049274 patent/WO2012027631A2/en not_active Ceased
- 2011-08-26 BR BR112013004458A patent/BR112013004458A2/pt not_active IP Right Cessation
- 2011-08-26 JP JP2013526167A patent/JP6097688B2/ja active Active
- 2011-08-26 RU RU2013113314/15A patent/RU2600891C2/ru active
- 2011-08-26 MX MX2013002268A patent/MX2013002268A/es unknown
- 2011-08-26 EP EP11820697.8A patent/EP2609429B1/en active Active
-
2018
- 2018-01-25 US US15/879,963 patent/US20180217158A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536442A5 (enExample) | ||
| CN105400868B (zh) | 使用miRNA检测体内细胞死亡情况的方法 | |
| CN109765378B (zh) | 一种新的肝硬化或肝纤维化标志物 | |
| RU2013113314A (ru) | Способы выявления антител против не4 и способы диагностики и/или прогнозирования состояний, ассоциированных с экспрессирующими не4 клетками | |
| CN101852804B (zh) | Gdf15蛋白的抗体的新用途 | |
| JP2012512389A5 (enExample) | ||
| JP6734191B2 (ja) | 早産のバイオマーカー | |
| JP2006500949A5 (enExample) | ||
| JP2010536372A5 (enExample) | ||
| EP3483290A1 (en) | Anellovirus genome quantification as a biomarker of immune suppression | |
| JP2019023645A5 (enExample) | ||
| JP2006518991A5 (enExample) | ||
| JP2010521655A5 (enExample) | ||
| JP2008509673A5 (enExample) | ||
| CN106164299A (zh) | 人类癌症中的tert和braf突变 | |
| CN103562404A (zh) | 预测肝癌预后的组合物或试剂盒以及预测肝癌预后的方法 | |
| RU2013104137A (ru) | Изоформы bard1 при раке легкого и колоректальном раке и их применение | |
| JP2012513584A5 (enExample) | ||
| CN105734070A (zh) | Corin基因变异体及其用途 | |
| JP2008547006A5 (enExample) | ||
| TW201317577A (zh) | 預測食道癌存活及癒後狀態之方法及其套組及微陣列晶片 | |
| CN103487580A (zh) | Dkk1作为诊断标志物的用途 | |
| JP2009523004A5 (enExample) | ||
| JP4576168B2 (ja) | 膀胱尿管逆流症または間質性膀胱炎の検査方法 | |
| JP5316749B2 (ja) | シスプラチン耐性遺伝子診断方法及びシスプラチン治療効果遺伝子診断キット |